- Home
- NECB vs TLSI Comparison
NECB vs TLSI Comparison
Compare NECB & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NECB
- TLSI
- Stock Information
- Founded
- NECB 1934
- TLSI 2010
- Country
- NECB United States
- TLSI United States
- Employees
- NECB N/A
- TLSI N/A
- Industry
- NECB Savings Institutions
- TLSI Medical Specialities
- Sector
- NECB Finance
- TLSI Health Care
- Exchange
- NECB Nasdaq
- TLSI Nasdaq
- Market Cap
- NECB 282.4M
- TLSI 244.3M
- IPO Year
- NECB N/A
- TLSI N/A
- Fundamental
- Price
- NECB $20.29
- TLSI $4.61
- Analyst Decision
- NECB
- TLSI Strong Buy
- Analyst Count
- NECB 0
- TLSI 3
- Target Price
- NECB N/A
- TLSI $10.67
- AVG Volume (30 Days)
- NECB 48.4K
- TLSI 92.7K
- Earning Date
- NECB 10-23-2025
- TLSI 11-13-2025
- Dividend Yield
- NECB 4.92%
- TLSI N/A
- EPS Growth
- NECB N/A
- TLSI N/A
- EPS
- NECB 3.21
- TLSI N/A
- Revenue
- NECB $102,569,000.00
- TLSI $40,207,000.00
- Revenue This Year
- NECB $1.90
- TLSI $57.25
- Revenue Next Year
- NECB $6.93
- TLSI $54.05
- P/E Ratio
- NECB $6.33
- TLSI N/A
- Revenue Growth
- NECB N/A
- TLSI 49.52
- 52 Week Low
- NECB $19.27
- TLSI $3.42
- 52 Week High
- NECB $31.72
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- NECB 50.62
- TLSI 47.90
- Support Level
- NECB $19.50
- TLSI $3.99
- Resistance Level
- NECB $20.53
- TLSI $4.54
- Average True Range (ATR)
- NECB 0.50
- TLSI 0.33
- MACD
- NECB 0.07
- TLSI -0.03
- Stochastic Oscillator
- NECB 80.17
- TLSI 57.66
About NECB NorthEast Community Bancorp Inc.
NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. It conducts activities throughout the Northeastern United States including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.